JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB124000

Native Clostridium difficile Toxoid A protein

Be the first to review this product! Submit a review

|

(0 Publication)

Native Clostridium difficile Toxoid A protein is a Clostridium difficile Full Length protein, expressed in Native, with >95%, suitable for SDS-PAGE.

View Alternative Names

toxA, tcdA, Toxin A

1 Images
SDS-PAGE - Native Clostridium difficile Toxoid A protein (AB124000)
  • SDS-PAGE

Unknown

SDS-PAGE - Native Clostridium difficile Toxoid A protein (AB124000)

SDS-PAGE showing ab124000 at 308 kDa.

Key facts

Purity

>95% SDS-PAGE

Expression system

Native

Tags

Tag free

Applications

SDS-PAGE

applications

Biologically active

No

Accession

P16154

Animal free

No

Carrier free

No

Species

Clostridium difficile

Reconstitution

Reconstitute in 250 µL of water

Storage buffer

pH: 7 - 8 Constituents: 5% Sucrose, 1.19% HEPES, 0.88% Sodium chloride

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

This protein is derived from a pathogenic organism, and may be involved in a disease process, consequently exposure may have adverse health effects.

Inactivation: Inactivated using formaldehyde. No cell rounding in the sensitive verocytotoxicity assay at 2µg/ml compared to active toxin lethal dose of 4pg/ml.

Sequence info

[{"sequence":"","proteinLength":"Full Length","predictedMolecularWeight":"308 kDa","actualMolecularWeight":null,"aminoAcidEnd":0,"aminoAcidStart":0,"nature":"Native","expressionSystem":null,"accessionNumber":null,"tags":[]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Avoid freeze / thaw cycle|Reconstitute for long term storage
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Clostridium difficile Toxoid A also known as TcdA is a major exotoxin produced by the Clostridium difficile bacterium. This protein functions mainly by disrupting the cytoskeleton structure through glycosylation of Rho GTPases which leads to cell rounding and cytotoxicity. TcdA has a molecular mass of approximately 308 kDa and tends to be expressed in the intestinal environment especially during infections associated with Clostridium difficile.
Biological function summary

TcdA plays an important role in pathogenesis by interfering with cellular signalling processes. While TcdA is known to independently affect cells it also acts in combination with another toxin TcdB to enhance the damaging effects on host tissues. This complex interaction results in increased permeability of intestinal epithelial cells contributing to inflammation and fluid accumulation.

Pathways

TcdA disrupts specific cellular pathways by inactivating small GTP-binding proteins such as Rho Rac and Cdc42. This action interrupts the actin cytoskeleton organization pathway which is critical for maintaining cellular structure and function. Additionally TcdA affects the MAPK signaling pathway thereby altering cellular responses to stress and inflammation. Proteins like MAPK play roles in mediating the downstream effects initiated by TcdA activity.

TcdA's effects are closely associated with antibiotic-associated diarrhea and pseudomembranous colitis. The cytotoxic actions of TcdA lead to severe inflammation of the colon resulting in symptoms characteristic of Clostridium difficile infections. TcdA also interacts with host proteins such as tight junction proteins causing disruption of the intestinal barrier and facilitating disease progression.

Specifications

Form

Lyophilized

Additional notes

Clostridium difficile Toxoid A is a highly purified preparation.

General info

Function

Toxin A. Precursor of a cytotoxin that targets and disrupts the colonic epithelium, inducing the host inflammatory and innate immune responses and resulting in diarrhea and pseudomembranous colitis (PubMed : 20844489). TcdA and TcdB constitute the main toxins that mediate the pathology of C.difficile infection, an opportunistic pathogen that colonizes the colon when the normal gut microbiome is disrupted (PubMed : 19252482, PubMed : 20844489). Compared to TcdB, TcdA is less virulent and less important for inducing the host inflammatory and innate immune responses (PubMed : 19252482). This form constitutes the precursor of the toxin : it enters into host cells and mediates autoprocessing to release the active toxin (Glucosyltransferase TcdA) into the host cytosol (By similarity). Targets colonic epithelia by binding to some receptor, and enters host cells via clathrin-mediated endocytosis (By similarity). Binding to LDLR, as well as carbohydrates and sulfated glycosaminoglycans on host cell surface contribute to entry into cells (PubMed : 16622409, PubMed : 1670930, PubMed : 31160825). In contrast to TcdB, Frizzled receptors FZD1, FZD2 and FZD7 do not act as host receptors in the colonic epithelium for TcdA (PubMed : 27680706). Once entered into host cells, acidification in the endosome promotes the membrane insertion of the translocation region and formation of a pore, leading to translocation of the GT44 and peptidase C80 domains across the endosomal membrane (By similarity). This activates the peptidase C80 domain and autocatalytic processing, releasing the N-terminal part (Glucosyltransferase TcdA), which constitutes the active part of the toxin, in the cytosol (PubMed : 17334356, PubMed : 19553670, PubMed : 27571750).. Glucosyltransferase TcdA. Active form of the toxin, which is released into the host cytosol following autoprocessing and inactivates small GTPases (PubMed : 22267739, PubMed : 22747490, PubMed : 24905543, PubMed : 30622517, PubMed : 7775453). Acts by mediating monoglucosylation of small GTPases of the Rho family (Rac1, RhoA, RhoB, RhoC, Rap2A and Cdc42) in host cells at the conserved threonine residue located in the switch I region ('Thr-37/35'), using UDP-alpha-D-glucose as the sugar donor (PubMed : 22267739, PubMed : 22747490, PubMed : 24905543, PubMed : 30622517, PubMed : 7775453). Monoglucosylation of host small GTPases completely prevents the recognition of the downstream effector, blocking the GTPases in their inactive form, leading to actin cytoskeleton disruption and cell death, resulting in the loss of colonic epithelial barrier function (PubMed : 7775453). Also able to catalyze monoglucosylation of some members of the Ras family (H-Ras/HRAS, K-Ras/KRAS and N-Ras/NRAS), but with much less efficiency than with Rho proteins, suggesting that it does not act on Ras proteins in vivo (PubMed : 30622517).

Sequence similarities

Belongs to the clostridial glucosylating toxin (LCGT) family.

Post-translational modifications

Toxin A. Undergoes autocatalytic cleavage to release the N-terminal part (Glucosyltransferase TcdA), which constitutes the active part of the toxin, in the host cytosol (PubMed:17334356, PubMed:19553670, PubMed:22267739, PubMed:27571750). 1D-myo-inositol hexakisphosphate-binding (InsP6) activates the peptidase C80 domain and promotes autoprocessing (PubMed:17334356, PubMed:19553670).

Product protocols

Target data

Toxin A. Precursor of a cytotoxin that targets and disrupts the colonic epithelium, inducing the host inflammatory and innate immune responses and resulting in diarrhea and pseudomembranous colitis (PubMed : 20844489). TcdA and TcdB constitute the main toxins that mediate the pathology of C.difficile infection, an opportunistic pathogen that colonizes the colon when the normal gut microbiome is disrupted (PubMed : 19252482, PubMed : 20844489). Compared to TcdB, TcdA is less virulent and less important for inducing the host inflammatory and innate immune responses (PubMed : 19252482). This form constitutes the precursor of the toxin : it enters into host cells and mediates autoprocessing to release the active toxin (Glucosyltransferase TcdA) into the host cytosol (By similarity). Targets colonic epithelia by binding to some receptor, and enters host cells via clathrin-mediated endocytosis (By similarity). Binding to LDLR, as well as carbohydrates and sulfated glycosaminoglycans on host cell surface contribute to entry into cells (PubMed : 16622409, PubMed : 1670930, PubMed : 31160825). In contrast to TcdB, Frizzled receptors FZD1, FZD2 and FZD7 do not act as host receptors in the colonic epithelium for TcdA (PubMed : 27680706). Once entered into host cells, acidification in the endosome promotes the membrane insertion of the translocation region and formation of a pore, leading to translocation of the GT44 and peptidase C80 domains across the endosomal membrane (By similarity). This activates the peptidase C80 domain and autocatalytic processing, releasing the N-terminal part (Glucosyltransferase TcdA), which constitutes the active part of the toxin, in the cytosol (PubMed : 17334356, PubMed : 19553670, PubMed : 27571750).. Glucosyltransferase TcdA. Active form of the toxin, which is released into the host cytosol following autoprocessing and inactivates small GTPases (PubMed : 22267739, PubMed : 22747490, PubMed : 24905543, PubMed : 30622517, PubMed : 7775453). Acts by mediating monoglucosylation of small GTPases of the Rho family (Rac1, RhoA, RhoB, RhoC, Rap2A and Cdc42) in host cells at the conserved threonine residue located in the switch I region ('Thr-37/35'), using UDP-alpha-D-glucose as the sugar donor (PubMed : 22267739, PubMed : 22747490, PubMed : 24905543, PubMed : 30622517, PubMed : 7775453). Monoglucosylation of host small GTPases completely prevents the recognition of the downstream effector, blocking the GTPases in their inactive form, leading to actin cytoskeleton disruption and cell death, resulting in the loss of colonic epithelial barrier function (PubMed : 7775453). Also able to catalyze monoglucosylation of some members of the Ras family (H-Ras/HRAS, K-Ras/KRAS and N-Ras/NRAS), but with much less efficiency than with Rho proteins, suggesting that it does not act on Ras proteins in vivo (PubMed : 30622517).
See full target information tcdA

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com